Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth-Sponsored Multivitamin Study Finds $1.6 Bil. Health Insurance Savings

This article was originally published in The Tan Sheet

Executive Summary

A recent cost analysis linking substantial health care savings to daily multivitamin use in consumers over 65 may aid in persuading insurers to cover such a regimen. The findings were released by Centrum marketer Wyeth Consumer Healthcare at an Oct. 2 briefing in Washington, D.C

You may also be interested in...



Aetna Medicare Rx Discount Card To Offer Discounts On All CMS Drugs

Aetna's Medicare Rx drug discount card includes a Vitamin Advantage program

Aetna Medicare Rx Discount Card To Offer Discounts On All CMS Drugs

Aetna's Medicare Rx drug discount card includes a Vitamin Advantage program

Aetna Medicare Rx Discount Card To Offer Discounts On All CMS Drugs

Aetna's Medicare Rx drug discount card includes a Vitamin Advantage program

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel